U.S. Trade Pressure Mounts on Swiss Pharmaceutical Pricing

The potential probe, highlighted by the industry body Interpharma, suggests that Switzerland’s ongoing review of domestic healthcare costs has placed it directly in the crosshairs of Washington. Federal officials are weighing whether these pricing strategies constitute unfair trade practices, mirroring the tension recently sparked by Berlin’s own legislative reforms aimed at curbing pharmaceutical spending.

Major Swiss exporters, specifically Roche and Novartis, face significant uncertainty if the U.S. follows through with tariff threats or trade sanctions. While pharmaceutical firms have pushed back against the aggressive stance of U.S. legislators, the political momentum to protect domestic market revenues remains a potent driver for this investigation. This policy shift indicates a widening conflict between European cost-cutting efforts and the profit mandates of the global drug industry.